Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone702-835-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$109.33 million
Profitability
Miscellaneous
Employees235
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.04. Spectrum Pharmaceuticals had a negative return on equity of 37.72% and a negative net margin of 109.76%. During the same quarter in the prior year, the business earned ($0.15) EPS. View Spectrum Pharmaceuticals' Earnings History.
When is Spectrum Pharmaceuticals' next earnings date?
What price target have analysts set for SPPI?
5 Wall Street analysts have issued twelve-month price targets for Spectrum Pharmaceuticals' stock. Their predictions range from $19.00 to $40.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $24.00 in the next year. This suggests a possible upside of 222.1% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.
What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.
What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "With the sale of marketed products, Spectrum Pharma lost a steady stream of revenues. Although the BLA for Rolonits was submitted last year, it was withdrawn in March 2019. Spectrum has faced regulatory setbacks in the past including rejection of regulatory application for Qapzola seeking approval for bladder cancer in the United States. Additional regulatory/development setbacks, especially related to Rolontis, could affect the stock. Spectrum’s shares have underperformed the industry in the past year. However, development of poziotinib is progressing well including in the phase II pivotal study in second-line lung cancer. Moreover, sale of its marketed products will help Spectrum to focus on and support the development of its pipeline candidates. Loss estimates remained stable ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/1/2019)
- 2. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019)
Has Spectrum Pharmaceuticals been receiving favorable news coverage?
News coverage about SPPI stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Spectrum Pharmaceuticals.
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), The Medicines (MDCO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), Intercept Pharmaceuticals (ICPT), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Myokardia (MYOK) and Ligand Pharmaceuticals (LGND).
What other stocks do shareholders of Spectrum Pharmaceuticals own?
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
- Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
- Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
- Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
Who are Spectrum Pharmaceuticals' major shareholders?
Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (9.88%), FMR LLC (1.91%), Candriam Luxembourg S.C.A. (0.93%), Rhumbline Advisers (0.26%), Arizona State Retirement System (0.15%) and SG Americas Securities LLC (0.13%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Which major investors are selling Spectrum Pharmaceuticals stock?
SPPI stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, DekaBank Deutsche Girozentrale, Fosun International Ltd, ClariVest Asset Management LLC, PNC Financial Services Group Inc., American International Group Inc. and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Which major investors are buying Spectrum Pharmaceuticals stock?
SPPI stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Candriam Luxembourg S.C.A., Tibra Equities Europe Ltd, Kennedy Capital Management Inc., Connor Clark & Lunn Investment Management Ltd., Primecap Management Co. CA, Los Angeles Capital Management & Equity Research Inc. and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Spectrum Pharmaceuticals.
How do I buy shares of Spectrum Pharmaceuticals?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of SPPI stock can currently be purchased for approximately $7.45.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $834.10 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.
What is Spectrum Pharmaceuticals' official website?
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
